Study endpoints
SD
DISEASE
The primary endpoint was the investigator-assessed disease control rate (DCR) for the initial 120 mg/day dosage, defined as the proportion of patients with best overall complete response (CR), partial response (PR), or stable disease (SD) based on the RECIST guidelines. DCR was analysed using the intention-to-treat analysis.Secondary endpoints were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), duration of treatment, and safety profile. Safety analysis was performed in the safety population, which comprised patients who received ≥ one dose of regorafenib.